Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time...
-
Government Policies and war in the Middle East, delivers jobs shock for the UK's young - and undermines business growth
-
ZymoChem has demonstrated that its bio-based and biodegradable SAP matches and surpasses the performance of conventional petroleum-based materials.
-
Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026....
-
4basebio PLC ("4basebio" or the "Company") Cambridge, UK, 31 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics,...
-
GEVORKYAN, a.s. pokračuje v rozširovaní portfólia a prináša nové technologické riešenia pre zákazníkov z úplne rôznych, navzájom neprepojených odvetví európskeho priemyslu. Pre dánsku značku audio...
-
GEVORKYAN, a.s. pokračuje v rozšiřování portfolia a přináší nová technologická řešení pro zákazníky z naprosto odlišných, vzájemně nepropojených odvětví evropského průmyslu. Pro dánskou značku audio...
-
GEVORKYAN, a.s. continues to expand its portfolio and brings new technological solutions for customers from completely different, mutually unrelated sectors of European industry. For a Danish audio...
-
Sangamo Therapeutics reports recent business highlights and fourth quarter and full year 2025 financial results
-
Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a...